Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Etavopivat (FT-4202) in Healthy Volunteers and Sickle Cell Disease
NCT03815695Phase 1Completed
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etavopivat in sickle cell disease (SCD) (6 arms), sponsored by Forma Therapeutics, Inc. Primary endpoints: Incidence, frequency, and severity of adverse events (AEs) per CTCAE v5.0 up to 3 weeks, Maximum observed plasma concentration up to 3 weeks and 9 more. Started Dec 2018; status: completed.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03815695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815695.